Veryan Medical has received a further £13.5m of funding in the form of both equity and debt from its existing investors, including Touchstone Innovations, Invesco Perpetual and Seroba Life Sciences. The debt element of the round has been provided by Silicon Valley Bank in the form of a €5m capital term loan.
This new funding follows several significant milestones for the company’s BioMimics 3D in 2016, including: the completion of enrolment into the MIMICS-2 IDE study in the USA, Germany and Japan; the publication of the results from the Mimics Randomised Controlled Trial in Circulation: Cardiovascular Interventions; and the first 50 subjects enrolled into the MIMICS-3D Registry.
Nooman Haque, director of Life Sciences and Healthcare, comments, “This smart technology (BioMimics 3D) could be transformative for patients suffering from arterial disease.”
